Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).
| Autor: | Wijesingha N; UCL Institute of Ophthalmology, London, UK.; Moorfields Eye Hospital NHS Foundation Trust, London, UK., Kotecha A; Roche Products Ltd., Welwyn Garden City, UK., Margaron P; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Sivaprasad S; UCL Institute of Ophthalmology, London, UK. sobha.sivaprasad@nhs.net.; Moorfields Eye Hospital NHS Foundation Trust, London, UK. sobha.sivaprasad@nhs.net. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Eye (London, England) [Eye (Lond)] 2024 Dec; Vol. 38 (18), pp. 3610. |
| DOI: | 10.1038/s41433-024-03309-5 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink